adalimumab products — Medica

Initial criteria

• age ≥ 5 years
• medication is prescribed by or in consultation with a gastroenterologist

Reauthorization criteria

• patient has been established on adalimumab therapy for ≥ 6 months
• when assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (e.g., fecal calprotectin, C‑reactive protein, endoscopic findings, reduced corticosteroid dose) OR improved symptom(s) such as decreased pain, fatigue, stool frequency, or rectal bleeding

Approval duration

initial 6 months, reauth 1 year